Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has demonstrated encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn. The Director, Clinical Development will report to the Senior Vice President, Clinical Development, providing IPF/ILD medical oversight, scientific leadership, and clinical expertise throughout the lifecycle of clinical trials, from protocol strategy and design through execution, data interpretation, clinical study reporting, and regulatory interactions. The Director, Clinical Development serves as the primary medical leader for assigned trials, with a strong focus on patient safety, scientific integrity, and clinical relevance. The Director, Clinical Development works cross-functionally with Clinical Operations, Biostatistics, Regulatory Affairs, Pharmacovigilance, Translational Science, Data Management, and external CROs to support effective trial execution and alignment with overall program strategy. This individual provides medical direction on protocol design, safety monitoring, risk mitigation, data review, and clinical trial amendments, while serving as a key medical resource for investigators and study teams. The role also leads medical review and interpretation of emerging safety and efficacy data, contributes to Clinical Study Reports and regulatory submissions, and supports health authority interactions, advisory boards, investigator meetings, publications, and scientific presentations.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director